BioCrine
  • Home
  • About Us
    • Company and People
    • Board of Directors
    • Management
    • Partners
  • Research Programs
    • Pipeline overview
    • Diabetes as a disease
    • Biocrine drug discovery strategy
    • Serum factor apoCIII
    • Insulin receptor isoforms
    • Calcium channels
    • Inositol pyrophosphates
  • InSight Technology
    • What is it?
    • How does it work?
    • Where can it be used?
  • News
  • Contact
Home » News » Publication » Agonistic aptamer to the insulin receptor leads to biased signaling and functional selectivity

Agonistic aptamer to the insulin receptor leads to biased signaling and functional selectivity

Agonistic aptamer to the insulin receptor leads to biased signaling and functional selectivity through allosteric modulation.

In this study IR-A48 is presented as a biased agonist able to selectively induce the metabolic activity of insulin receptors through allosteric binding. This is the first study to show that aptamer–protein interactions can not only differentially modulate receptor autophosphorylation (IR Y1150), but also induce specific signaling pathways and functional selectivity. Data suggests that aptamers can be a promising tool for developing artificial biased agonists to targeted receptor and that IR-A48 could represent a novel strategy for facilitating insulin action and improving glycemic control in diabetes patients.
The results have been published in the September issue of Nucleic Acids Research.

Read more:    Agonistic aptamer to the insulin receptor leads to biased signaling and functional selectivity through allosteric modulation. Na-Oh Yunn, Ara Koh, Seungmin Han, Jong Hun Lim, Sehoon Park, Jiyoun Lee, Eui Kim, Sung Key Jang, Per-Olof Berggren and Sung Ho Ryu. Nucleic Acids Research, 2015 Sep 18; Vol. 43, No. 16, 7688-7701, doi: 10.1093/nar/gkv767

September 2, 2020 Catharina Rahm

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Categories

Recent posts

  • Professor Berggren’s research publications
    Professor Berggren’s research publications February 6, 2025
  • Årsstämma 17 juni 2024
    Årsstämma 17 juni 2024 June 2, 2024
  • Researchers use the eye as a window to study liver health
    Researchers use the eye as a window to study liver health February 8, 2024
  • ERC Proof of Concept to Professor Per-Olof Berggren
    ERC Proof of Concept to Professor Per-Olof Berggren February 7, 2024
  • The anterior chamber of the eye as a servant to medical research in translation
    The anterior chamber of the eye as a servant to medical research in translation February 7, 2024
  • Lisa Juntti-Berggren receives the Swedish Society of Medicine’s Jubilee Prize
    Lisa Juntti-Berggren receives the Swedish Society of Medicine’s Jubilee Prize February 7, 2024
  • Eye implant may be used to treat diabetes
    Eye implant may be used to treat diabetes February 7, 2024
  • Årsstämma 16 juni 2023
    Årsstämma 16 juni 2023 May 29, 2023
  • New strategy to preserve insulin-producing cells in diabetes
    New strategy to preserve insulin-producing cells in diabetes August 19, 2022
  • Kallelse till årsstämma 27 juni 2022
    Kallelse till årsstämma 27 juni 2022 June 6, 2022

Biocrine AB

Box 3073

169 03 Solna, Sweden

Contact Us

info at biocrine.se

www.biocrine.com

Copyright © 2012 Biocrine AB. All Rights Reserved